Mandate

Vinge has advised Vimian Group in connection with its rights issue

March 12, 2024

Vinge has advised Vimian Group AB (publ) in connection with a partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633 billion before deduction of transaction costs.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. At Vimian, one believes that every animal deserves the best available care. Vimian brings pioneering businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners.

Vinge’s team consisted of Dain Hård NevonenLinnéa Sellström, Anna Svensson, Michaela Ådén and Alexander Rüdén.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026